3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
16
Phase 3
11
Phase 1
7
Phase 4
2
Phase 2/3
1
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
34
Ovarian Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
4
Endometrial Neoplasms
4
Uterine Cervical Neoplasms
3
Neoplasms
3
Hereditary Sensory and Autonomic Neuropathies
3
Prostatic Neoplasms
2
Neoplasms by Site
2
Head and Neck Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Breast Diseases
2
Advanced Solid Tumors
2
Triple Negative Breast Neoplasms
1
Spinocerebellar Degenerations
1
Solid Tumor, Adult
1
Neoplasm Metastasis
1
Melanoma
1
HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer
1
HR+/HER2- Breast Cancer
1
HER2-positive Metastatic Breast Cancer
1
HER2-positive Breast Cancer
1
Fallopian Tube Neoplasms
1
Estrogen Receptor Positive Breast Cancer
1
Esophageal Squamous Cell Carcinoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Ductal, Breast
1
Brain Neoplasms
1
Interventions
pembrolizumab
43
Nivolumab
24
Gemcitabine
23
Cyclophosphamide
21
Paclitaxel
17
Capecitabine
16
fludarabine
14
Ipilimumab
14
aldesleukin
11
Docetaxel
11
130-nm albumin-bound paclitaxel
11
Trastuzumab
10
Cetuximab
10
Bevacizumab
10
Albumin-Bound Paclitaxel
9
fludarabine phosphate
8
Specimen Handling
8
Interleukin-2
8
Fluorouracil
8
Cisplatin
8
Biopsy
8
Radiosurgery
7
Oxaliplatin
7
Irinotecan
7
durvalumab
6
avelumab
6
Temozolomide
6
Pemetrexed
6
Leucovorin
6
Carboplatin
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Neoplasm Metastasis
×
Fulvestrant
×
Clear all
NCT05735080
2026-04-01
INX-315-01
Incyclix Bio
Phase 1/2
Recruiting
150 enrolled